霸王茶姬大跌登顶热搜！周五美股盘中股价一度暴跌近16%创历史新低，深夜发长文回应“咖啡因”质疑，收盘跌幅收窄至2.54%

Core Viewpoint - The stock price of Bawang Chaji (霸王茶姬) fell sharply, reaching a new low since its listing, primarily due to a controversy surrounding caffeine content in its products, which has led to consumer complaints about health issues [1][3]. Stock Performance - On December 26, Bawang Chaji's stock opened down nearly 16%, closing at a 2.54% decrease, with a market capitalization of approximately 2.18 billion [1][2]. Consumer Concerns - A significant number of consumers have reported symptoms such as palpitations and insomnia after consuming Bawang Chaji's products, leading to accusations that the caffeine content is dangerously high [3]. Company Response - Bawang Chaji issued a statement addressing these concerns, asserting that the caffeine content in their tea is comparable to that of a latte and significantly lower than that of an Americano [5][6]. - The company emphasized that tea contains various beneficial compounds, including polyphenols and minerals, which contribute to its health benefits and flavor, and that caffeine is not the only active ingredient [7][8]. Product Innovation - The company has been exploring ways to reduce caffeine content, having introduced a product line that lowers caffeine by approximately 50% while maintaining the core flavor of tea [8][9]. - Bawang Chaji is also investigating the possibility of creating caffeine-free tea options to cater to consumers sensitive to caffeine [9]. Cultural Significance - The company highlighted the cultural importance of tea and its historical journey, drawing parallels with coffee's evolution and emphasizing the need for genuine product development and cultural confidence to promote Chinese tea globally [9][10].